Fulltext

Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab

Lenihan, D. ; Suter, T. ; Brammer, M. ; Neate, C. ; Ross, G. ; Baselga, J.

In: Annals of Oncology, 2012, vol. 23, no. 3, p. 791-800

Zum persönliche Liste hinzufügen
    Titel
    • Pooled analysis of cardiac safety in patients with cancer treated with pertuzumab
    Autor
    • Lenihan, D.. Department of Cardiovascular Medicine, Vanderbilt University, Nashville, USA
    • Suter, T.. Department of Cardiology, Cardio-Oncology, Bern University Hospital and University of Bern, Bern, Switzerland
    • Brammer, M.. US Medical Affairs, BioOncology, Genentech, Inc., South San Francisco, USA
    • Neate, C.. Pharmaceutical Development, Biostatistics
    • Ross, G.. Pharmaceutical Development Oncology,Roche Products Ltd, Welwyn Garden City, UK
    • Baselga, J.. Department of Medicine, Harvard Medical School
    Dokumententyp
    • Postprint
    Sprache
    • Englisch
    Veröffentlicht in
    • Annals of Oncology, 2012, vol. 23, no. 3, p. 791-800. Oxford University Press
    Andere elektronische Ausgabe
    OAI-PMH-ID
    • oai:doc.rero.ch:293869
    Summary
    Background: Pertuzumab, a human epidermal growth factor receptor (HER) 2 dimerization inhibitor, has demonstrated promising efficacy in combination with trastuzumab in patients with metastatic breast cancer. As HER signaling pathways are not only involved in oncogenesis, but also in myocardial homeostasis, an analysis of cardiac safety data was undertaken in a large group of patients treated with pertuzumab. Patients and methods: A complete database of patients treated with full-dose pertuzumab was used to describe the incidence of asymptomatic left ventricular systolic dysfunction (LVSD) and symptomatic heart failure (HF). Results: Information for 598 unique patients was available for the current analysis. Of the patients treated with pertuzumab alone (n = 331) or pertuzumab in combination with a non-anthracycline-containing cytotoxic (n = 175) or trastuzumab (n = 93), 23 (6.9%), 6 (3.4%), and 6 (6.5%), respectively, developed asymptomatic LVSD and 1 (0.3%), 2 (1.1%), and 1 (1.1%), respectively, displayed symptomatic HF. None of the 15 patients receiving both pertuzumab and erlotinib demonstrated LVSD. Conclusions: Patients treated with pertuzumab experienced relatively low levels of asymptomatic LVSD or symptomatic HF. There was no notable increase in cardiac side-effects when pertuzumab was given in combination with other anticancer agents